In the absence of a federal tax credit for investing in biotech companies, many states have filled the void by offering generous incentives for investing in qualified startups. A federal bill that would offer such an incentive—the Innovative Technologies Investment Incentive Act of 2011 (H.R. 1732)—is reportedly modeled on Maryland’s program. But the measure has gained no traction since being introduced.
Maryland offers a biotechnology investment tax credit that is a refundable tax credit equal to 50 percent of an eligible investment made in a qualified biotechnology company during the tax year, not to exceed $250,000. Among other requirements, a qualified biotechnology company's securities must not be publicly traded on an exchange. In addition, the company must have been in active business for no more than 10 years.
The state recently adopted final rules for the biotechnology investment tax credit that clarify the requirements and procedures for a biotechnology company to be certified as a qualified Maryland biotechnology company, a Bloomberg BNA Weekly State Tax Reportarticle noted.
The New York Department of Taxation and Finance recently issued a technical memorandum clarifying the requirements for claiming the qualified emerging technology company (QETC) facilities, operations, and training credit, according to another Bloomberg BNA Weekly State Tax Reportarticle. “Emerging technologies” include biotechnologies.
The business must meet the following requirements to claim the credit: have no more than 100 employees, 75 percent of which are employed in the state; have a ratio of research and development funds to net sales equal to at least 6 percent; have gross revenue of $20 million or less for the tax year immediately preceding the year in which the taxpayer is claiming the credit; and qualify as a QETC specifically for the activities listed in N.Y. Pub. Authorities Law Section 3102-e(1)(b), which includes biotechnologies.
Arkansas, California, Colorado, Connecticut, Hawaii, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, Rhode Island, and Washington also offer biotechnology tax credits, according to the Bloomberg BNA State Tax Portfolios.
In other developments . . .
The Oregon Department of Energy adopted permanent rules to administer the alternative fuel vehicle infrastructure tax credit within the Energy Incentives Program, according to an article in the Bloomberg BNA Weekly State Tax Report.
By: Kathleen Caggiano
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)